Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

PORTABLE IMAGING DEVICE FOR PROSTATE CANCER DETECTION

Award Number: R44CA082620
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/1999
PERIOD OF PERFORMANCE END DATE: 07/31/2012

Group Awards By:

View Award Description

PORTABLE IMAGING DEVICE FOR PROSTATE CANCER DETECTION - DESCRIPTION (provided by applicant): The long-term goal of the project is to bring to the market a new tool for prostate cancer screening, the Prostate Mechanical Imager (PMI), which provides real time 3-D reconstruction of prostate capturing its geometrical and mechanical characteristics and aids in detecting tissue abnormalities. The current PMI prototype has undergone several progressions of hardware and software development leading to the final device concept validated in model experiments and in clinical studies which have yielded promising results. ProUroScanTM is the first PMI commercial device to be developed, clinically tested and submitted for FDA approval in the course of the proposed project. Digital records obtained by ProUroScanTM could be used to document palpable prostate abnormalities and to monitor disease progression over time. The ProUroScanTM will include a transrectal probe comprising force sensor arrays and a motion tracking system, a compact electronic unit with single electronic board powered through USB port from a laptop with touch screen capability and a wireless color printer. As a separate component, an automatic calibration setup for tactile sensor testing, tuning and calibration will be designed and built. Specific aims of the proposed project include PMI hardware and software refinements. The hardware development will include several technological improvements in the PMI transrectal probe and data acquisition board. Software for prostate 3-D real-time reconstruction and nodule detection will be refined and validated. Substantial amount of effort will be committed to assure the activities and resulting design of the PMI development comply with regulatory requirements. A key focus of pre-commercialization engineering will be on completing the design history file, verification, validation and safety certification testing. Two-stage clinical studies will be conducted at the Robert Wood Johnson Medical Center (New Brunswick, NJ) and at VA Medical Center (Minneapolis, MN) to document system safety and efficacy. The focal point of all proposed activities and the endpoint of the grant will be preparation and submission of the PMA application for the FDA approval of PMI. The core partnership was established between Artann and ProUroCare, publicly traded medical device company, to ensure commercialization success of the PMI. ProUroCare has committed necessary financial and managerial resources for regulatory clearance and commercialization of the PMI technology to complement NIH support of the project. There is a $50 billion prostate-related market with estimated 40 - 60 milion adult males suffering from one or more prostate conditions. Industry analysts believe that only 10 - 15% of incidents are reported, stressing the urgent need for new screening technologies. The goal of this project is to develop ProUroScanTM, a cost- effective, portable and easy-to-use imaging device for detecting and documenting palpable prostate abnormalities and monitoring disease progression over time.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2011 ( Subtotal = $0 )
2011	2008	ARTANN LABORATORIES	1753 LINVALE-HARBOURTON RD	LAMBERTVILLE	NJ	08530	HUNTERDON	USA	Cancer Treatment Research	000	6	8/5/2011	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2010 ( Subtotal = $0 )
2010	2008	ARTANN LABORATORIES	1753 LINVALE-HARBOURTON RD	LAMBERTVILLE	NJ	08530	HUNTERDON	USA	Cancer Treatment Research	000	6	5/11/2010	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2009 ( Subtotal = $299,994 )
2009	2009	ARTANN LABORATORIES	1753 LINVALE-HARBOURTON RD	LAMBERTVILLE	NJ	08530	HUNTERDON	USA	Trans-NIH Recovery Act Research Support	000	6	9/30/2009	SUPPLEMENT FOR EXPANSION	$299,994
														Subtotal = $299,994

Issue Date FY: 2008 ( Subtotal = $1,000,000 )
2008	2008	ARTANN LABORATORIES	1753 LINVALE-HARBOURTON RD	LAMBERTVILLE	NJ	08530	HUNTERDON	USA	Cancer Treatment Research	000	6	7/2/2008	NON-COMPETING CONTINUATION	$1,000,000
														Subtotal = $1,000,000

Issue Date FY: 2007 ( Subtotal = $1,000,000 )
2007	2007	ARTANN LABORATORIES	1753 LINVALE-HARBOURTON RD	LAMBERTVILLE	NJ	08530	HUNTERDON	USA	Cancer Treatment Research	000	5	8/1/2007	NON-COMPETING CONTINUATION	$1,000,000
														Subtotal = $1,000,000

Issue Date FY: 2006 ( Subtotal = $1,000,000 )
2006	2006	ARTANN LABORATORIES	1753 LINVALE-HARBOURTON RD	LAMBERTVILLE	NJ	08530	HUNTERDON	USA	Cancer Treatment Research	000	4	9/29/2006	COMPETING CONTINUATION	$1,000,000
														Subtotal = $1,000,000

Issue Date FY: 2003 ( Subtotal = $460,157 )
2003	2003	ARTANN LABORATORIES	1753 LINVALE-HARBOURTON RD	LAMBERTVILLE	NJ	08530	HUNTERDON	USA	Cancer Treatment Research	000	3	7/2/2003	NON-COMPETING CONTINUATION	$460,157
														Subtotal = $460,157

Issue Date FY: 2002 ( Subtotal = $438,598 )
2002	2002	ARTANN LABORATORIES	1753 LINVALE-HARBOURTON RD	LAMBERTVILLE	NJ	08530	HUNTERDON	USA	Cancer Treatment Research	000	2	8/6/2002	COMPETING CONTINUATION	$438,598
														Subtotal = $438,598

Grand Total All Awards = $4,198,749

Top

All Categories

About

Search

Reports

Data Submission

Award Information

PORTABLE IMAGING DEVICE FOR PROSTATE CANCER DETECTION

Award Number: R44CA082620

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/1999

PERIOD OF PERFORMANCE END DATE: 07/31/2012

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer